INPROPIB is developing a new range of fish-based products that are healthy and effective at treating obesity, the metabolic syndrome and other associated cardiovascular pathologies.
INPROPIB will continue to advance on researching the identified functional ingredients in order to detect which ingredient or what combination of ingredients causes a greater beneficial effect and in order to identify what mechanisms of the metabolism are involved in improving the quality of life of patients with obesity or the metabolic syndrome. Likewise, during the project, the anxiolytic and anti-depressive potential of the newly developed products will be evaluated, given the anxiolytic potential of the bioactive ingredients under analysis and the association between obesity and psychological disorders such as stress and anxiety.
The project offers new future prospects for the fishing sector, thereby allowing it to recover consumption and increase the competitiveness of the sector through new products.
INPROPIB relies on a consortium participated by Eurecat, which collaborates on the project through the Technological Unit of Nutrition and Health. Eurecat is delving into the biological action mechanisms involved in the physiological effects of the combination of functional ingredients, and it is researching the potential anxiolytic effect of the developed products, which is beneficial in supporting weight-loss diets that cause states of anxiety.